NEW YORK (GenomeWeb News) – BD Diagnostics said today that Italian biotech and molecular diagnostics company Biodiversity will develop and commercialize tests tailored for BD's platform for the detection of infections in transplant patients, as part of a regional collaboration.
Biodiversity will develop a portfolio of molecular assays to run on the BD Max System's open architecture. The assays will be for patients who have undergone transplants.
Following a transplant, patients are often given drugs to suppress their immune systems to prevent rejection. This, however, puts a patient at higher risk for infection.
"Early and accurate diagnosis of infection is often essential to monitor and protect patient health following a transplant procedure," BD said, and the assays being developed under today's collaboration can expand the testing capabilities for molecular laboratories, which, in turn, can lead to faster testing results and earlier diagnosis for transplant patients.
The assays are planned for CE marking for sale and distribution in Europe. Commercialization of the assays in additional regions is expected to follow.
“This [testing technology] will empower laboratories with a new choice to improve the efficiency, accuracy, and speed to diagnose these types of infections," Tom Polen, President of BD Diagnostics – Diagnostic Systems, said in a statement.
BD Diagnostics is a segment of Becton Dickinson.
Financial and other terms of the deal were not disclosed.